Imikhiqizo Izigaba

Imikhiqizo efakiwe

Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo

I-Telmisartan I-antihypertensive Protecting renal engcono

I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition

I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba

I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa

0102030405

I-Telmisartan I-antihypertensive Protecting renal engcono

Intengo yesithenjwa: USD 0.2-0.8/g

Igama Lomkhiqizo I-Telmisartan
Inombolo ye-CAS. 144701-48-4
MF I-C33H30N4O2
MW 514.629
EINECS 1592732-453-0

Xhumana nathi

imininingwane yomkhiqizo

Incazelo Eningiliziwe

I-Telmisartan, eyaziwa nangokuthi i-Timosartan, iyinoveli yomuthi owehlisa umfutho wegazi ohlukaniswa njengomphikisi othize we-angiotensin II receptor (uhlobo lwe-AT1). Isetshenziswa kabanzi ekwelapheni umfutho wegazi ophakeme obalulekile, enikeza izinzuzo ezimbalwa kuneminye imithi ye-antihypertensive. Le ndatshana ihlose ukuhlinzeka ngemininingwane ebanzi yezinzuzo ze-Telmisartan kanye nokucatshangelwa okubalulekile kokusetshenziswa kwayo.

Izinzuzo ze-Telmisartan:

Umphumela ongcono we-antihypertensive:

I-Telmisartan isidakamizwa esivame ukunqunywa somugqa wokuqala we-antihypertensive ngenxa yokusebenza kwayo okuphezulu. Njengombangi wohlobo lwe-AT1, ivimbela isenzo se-angiotensin, okuholela ekwehleni okukhulu komfutho wegazi. I-Telmisartan ikhombisa izinga eliphakeme lokucaciswa uma kuqhathaniswa namanye ama-sartan, okuyivumela ukuthi ingene kalula kulwelwesi lwamaseli futhi iqondise kumaseli athile. Lokhu kucacisa kuthuthukisa imiphumela yayo ye-antihypertensive, okuholela ekwehleni okukhulu komfutho wegazi. Ukwengeza, i-Telmisartan inesigamu sempilo ende, iqinisekisa ukulawulwa okuqhubekayo nokuphumelelayo komfutho wegazi.

Ukuvikelwa kwemithambo yenhliziyo kanye ne-cerebral:

I-Telmisartan igqama njengowukuphela kwesidakamizwa esifana ne-sartan esigunyazwe yi-FDA ngezici zayo zokuvikela inhliziyo nemithambo yegazi. Ibonisa ikhono lokubuyisela emuva i-hypertrophy ye-ventricular kwesokunxele futhi inconywa ezigulini ezinomfutho wegazi ophakeme ohambisana ne-left ventricular hypertrophy, ukungasebenzi kahle kwenhliziyo, noma isifo se-coronary artery. Ngokungeziwe emiphumeleni yayo yokwehlisa umfutho wegazi, i-Telmisartan yehlisa ukulimala kwenhliziyo kanye ne-cerebrovascular. Kuwusizo ikakhulukazi kubantu abaye babhekana ne-stroke noma i-cardiac infarction.

Ukuvikela ukusebenza kwezinso:

Enye inzuzo yeTelmisartan wumthelela wayo omuhle ekusebenzeni kwezinso. Njengoba i-Telmisartan ingena ku-hepatic metabolism futhi ikhishwa ku-bile, inomthelela omncane ekusebenzeni kwezinso. Ngaphezu kwalokho, i-Telmisartan itholakele yehlisa i-proteinuria, ngaleyo ndlela ivikele ukusebenza kwezinso. Iwusizo ikakhulukazi ezigulini ezinomfutho wegazi ophakeme kanye nezimo ezihambisanayo ezifana ne-nephropathy yesifo sikashukela, i-microalbuminuria, i-proteinuria, noma ukungasebenzi kahle kwezinso okumaphakathi.

Ukuthuthukiswa kokumelana ne-insulin:

I-Telmisartan ibonise imiphumela emihle ku-glucose metabolism kanye nokumelana ne-insulin. Lesi sici sikwenza kube inketho efanelekile ezigulini ezinomfutho wegazi ophakeme kanye nesifo sikashukela, ngoba singasiza ekuthuthukiseni ukuzwela kwe-insulin nokulawulwa kweglucose.

I-Telmisartan, isitha esithile se-angiotensin II receptor (uhlobo lwe-AT1), inikeza izinzuzo ezimbalwa ekwelapheni umfutho wegazi ophakeme. Umphumela wayo ongcono we-antihypertensive, ukuvikelwa kwemithambo yenhliziyo nemithambo yobuchopho, ukulondolozwa kokusebenza kwezinso, nokuthuthukiswa kokungazweli kwe-insulin kwenza kube ukukhetha okubalulekile ekulawuleni umfutho wegazi ophakeme kanye nezimo ezihambisana nakho. Kodwa-ke, kubalulekile ukulandela imihlahlandlela enconyiwe mayelana nesikhathi somuthi, ukulawulwa komthamo, kanye nokuqapha okuvamile ukuze kuqinisekiswe ukusebenza kahle nokuphepha okuphelele. Ukubonisana nochwepheshe bezempilo kuhlala kwelulekwa ukuze uthole izeluleko eziqondene nawe kanye nesiqondiso mayelana nokusetshenziswa kwe-Telmisartan nanoma yimuphi umuthi.

Ukucaciswa

Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo

I-Telmisartan I-antihypertensive Protecting renal engcono

I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition

I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba

I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa

I-Telmisartan I-antihypertensive Protecting renal engcono

Incazelo Eningiliziwe

Ukucaciswa

I-Fluoxetine Hydrochloride yelapha ukucindezeleka I-Fluoxetine HCl I-Raw Powder 99% Prozac

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Phenylpiracetam Nootropic Supplement Phenylpiracetam Hydrazide powder

I-CARBETOCIN I-Postpartum Hemorrhage powder

I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

I-rosuvastatin antilipemic ejenti I-Rosuvastatin yelapha i-dyslipidemia